Contrarius Group Holdings’s Biogen BIIB Stock Holding History

Contrarius Group Holdings’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-64,952	Closed	-$11.4M	–	42
2025 Q4	$11.4M	Buy	+64,952	New	+$10.6M	0.55%	25

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Contrarius Group Holdings's BIIB Position: Q1 2026 in Review

Contrarius Group Holdings sold out of Biogen (BIIB) in Q1 2026, closing a stake of 64,952 shares — an estimated $11.4M sold.

Contrarius Group Holdings first reported a position in BIIB in Q4 2025 and held it in 1 quarter. The position peaked at $11.4M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Contrarius Group Holdings reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Contrarius Group Holdings sold 64,952 Biogen shares in Q1 2026, an estimated $11.4M.
Contrarius Group Holdings first reported a position in Biogen in Q4 2025 and held it in 1 quarter.
Contrarius Group Holdings's Biogen position peaked at $11.4M in Q4 2025.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Contrarius Group Holdings's 13F filing for Q1 2026, filed 11 May 2026.